Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $9.60 and traded as high as $9.93. Astellas Pharma shares last traded at $9.65, with a volume of 268,454 shares traded.
Astellas Pharma Stock Up 2.4 %
The company has a market cap of $17.46 billion, a price-to-earnings ratio of -43.86 and a beta of 0.31. The firm has a 50-day moving average price of $9.60 and a 200 day moving average price of $10.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. Sell-side analysts predict that Astellas Pharma Inc. will post 0.42 EPS for the current year.
Astellas Pharma Company Profile
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
